 | ||||||
| in | ||||||
| WEB | ||||||
| First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer Patients were randomly assigned in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four 21-day cycles ...
| ||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
ShareThis
No comments:
Post a Comment